Clementia Pharmaceuticals Inc.

Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare bone diseases and other musculoskeletal disorders. The company's lead product, palovarotene, aims to treat Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic disorder characterized by the abnormal formation of bone in muscles, tendons, and other connective tissues. Through rigorous clinical trials and research efforts, Clementia seeks to address unmet medical needs while improving the quality of life for affected patients. The company's commitment to scientific excellence and patient advocacy is central to its mission.